Sequel Med Tech made waves in March when it announced that its automated insulin delivery system had received FDA approval.
Despite its short history, the company was founded just last year, and has a wealth of expertise across a number of channels.
CEO Dr. Alan Rotvin has decades of experience in interventional cardiology, specialty medicine and as EVP of CVS’s Caremark pharmacy benefits management business, and is a co-founder of Sequel.
DEKA R&D developed the drug-delivery technology underlying the twiist, which is sold by Sequel. Sequel co-founder and DEKA founder Dean Kamen commercialized the first wearable insulin pump for people with diabetes. He said in March that the system “represents the next generation of insulin delivery.”
talk Drug Delivery Business News Speaking at the American Diabetes Association’s scientific conference in Orlando, Florida, Rotvin explained how the Manchester, New Hampshire-based company is looking to establish itself in the automated insulin delivery space.
“All AID systems are [an insulin pen] “Penn is great,” Rotvin said, “but that doesn’t mean there isn’t room for improvement. There’s still a lot of work to be done.”
For more information, please visit our sister site, Drug Delivery Business News.
